Mirum Pharmaceuticals, Inc.
DE ˙ DB ˙ US6047491013
77,12 € ↑0,96 (1,26%)
2026-06-05
DEL PRIS
SecurityDE:08D / Mirum Pharmaceuticals, Inc.
InstitutionDeutsche Bank Ag\
Latest Disclosed Ownership50,045 shares
Latest Disclosed Value $ 4,623,158
Deutsche Bank Ag\ reports 73.20% decrease in ownership of 08D / Mirum Pharmaceuticals, Inc.

On May 6, 2026 - Deutsche Bank Ag\ filed a 13F-HR form disclosing ownership of 50,045 shares of Mirum Pharmaceuticals, Inc. (DE:08D) valued at $3,753,375 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 11, 2026 disclosing 186,712 shares of Mirum Pharmaceuticals, Inc.. This represents a change in shares of -73.20% during the quarter. The current value of the position is $3,859,470 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-06 2026-03-31 13F MIRUM PHARMACEUTICALS COM 604749101 50,045 -136,667 -73.20 4,623 -68.65 0.0015
2026-02-11 2025-12-31 13F MIRUM PHARMACEUTICALS COM 604749101 186,712 2,382 1.29 14,748 9.14 0.0048
2025-11-13 2025-09-30 13F MIRUM PHARMACEUTICALS COM 604749101 184,330 28,703 18.44 13,513 70.64 0.0045
2025-08-12 2025-06-30 13F MIRUM PHARMACEUTICALS COM 604749101 155,627 -85,117 -35.36 7,920 -26.98 0.0029
2025-05-09 2025-03-31 13F MIRUM PHARMACEUTICALS COM 604749101 240,744 71,421 42.18 10,846 54.91 0.0043
2025-06-30 2024-12-31 13F/A-1 MIRUM PHARMACEUTICALS COM 604749101 169,323 12,060 7.67 7,002 14.15 0.0027
2025-02-14 2024-12-31 13F MIRUM PHARMACEUTICALS COM 604749101 169,323 12,060 7,002 0.0027
2025-06-26 2024-09-30 13F/A-1 MIRUM PHARMACEUTICALS COM 604749101 157,263 -91,788 -36.86 6,133 -27.97 0.0025
2024-11-13 2024-09-30 13F MIRUM PHARMACEUTICALS COM 604749101 157,263 -91,788 6,133 0.0025
2025-06-12 2024-06-30 13F/A-1 MIRUM PHARMACEUTICALS COM 604749101 249,051 4,900 2.01 8,515 38.84 0.0038
2024-08-14 2024-06-30 13F MIRUM PHARMACEUTICALS COM 604749101 249,051 4,900 8,515 0.0038
2025-06-02 2024-03-31 13F/A-1 MIRUM PHARMACEUTICALS COM 604749101 244,151 72,625 42.34 6,133 21.13 0.0028
2024-05-15 2024-03-31 13F MIRUM PHARMACEUTICALS COM 604749101 244,151 72,625 6,133 0.0028
2024-02-14 2023-12-31 13F MIRUM PHARMACEUTICALS COM 604749101 171,526 157,162 1,094.14 5,063 1,017.66 0.0026
2023-11-24 2023-09-30 13F/A-1 MIRUM PHARMACEUTICALS COM 604749101 14,364 -97,047 -87.11 454 -84.28 0.0003
2023-11-09 2023-09-30 13F MIRUM PHARMACEUTICALS COM 604749101 14,364 -97,047 454 0.0001
2023-08-14 2023-06-30 13F MIRUM PHARMACEUTICALS COM 604749101 111,411 48,020 75.75 2,882 89.36 0.0015
2023-05-15 2023-03-31 13F MIRUM PHARMACEUTICALS COM 604749101 63,391 4,256 7.20 1,523 32.00 0.0008
2023-02-13 2022-12-31 13F MIRUM PHARMACEUTICALS COM 604749101 59,135 51,123 638.08 1,153 586.31 0.0007
2022-11-14 2022-09-30 13F MIRUM PHARMACEUTICALS COM 604749101 8,012 -68,013 -89.46 168 -88.65 0.0001
2022-08-11 2022-06-30 13F MIRUM PHARMACEUTICALS COM 604749101 76,025 5,994 8.56 1,480 -4.02 0.0008
2022-05-13 2022-03-31 13F MIRUM PHARMACEUTICALS COM 604749101 70,031 -240 -0.34 1,542 37.56 0.0007
2022-02-16 2021-12-31 13F/A-1 MIRUM PHARMACEUTICALS COM 604749101 70,271 -9,755 -12.19 1,121 -29.67 0.0005
2022-02-11 2021-12-31 13F MIRUM PHARMACEUTICALS COM 604749101 70,271 -9,755 1,121 0.0001
2021-11-04 2021-09-30 13F MIRUM PHARMACEUTICALS COM 604749101 80,026 -62 -0.08 1,594 15.09 0.0008
2021-08-11 2021-06-30 13F MIRUM PHARMACEUTICALS COM 604749101 80,088 -1,237 -1.52 1,385 -14.08 0.0007
2021-05-13 2021-03-31 13F MIRUM PHARMACEUTICALS COM 604749101 81,325 9,545 13.30 1,612 28.65 0.0009
2021-02-16 2020-12-31 13F MIRUM PHARMACEUTICALS COM 604749101 71,780 69,135 2,613.80 1,253 2,356.86 0.0008
2020-11-12 2020-09-30 13F MIRUM PHARMACEUTICALS COM 604749101 2,645 252 10.53 51 8.51 0.0000
2020-08-13 2020-06-30 13F MIRUM PHARMACEUTICALS COM 604749101 2,393 743 45.03 47 104.35 0.0000
2020-05-14 2020-03-31 13F MIRUM PHARMACEUTICALS COM 604749101 1,650 753 83.95 23 9.52 0.0000
2020-02-14 2019-12-31 13F MIRUM PHARMACEUTICALS COM 604749101 897 185 25.98 21 250.00 0.0000
2019-11-14 2019-09-30 13F MIRUM PHARMACEUTICALS COM 604749101 712 712 6 0.0000
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.